Atom Therapeutics
Atom Therapeutics is a clinical stage biotechnology company founded in 2012. Atom is developing best-in-class orally delivered small molecule drugs for treatment of inflammatoryand metabolic diseases, such as chronic gout, for which there are no effective treatments. Atom’s lead therapy, ABP-671, for chronic gout, is more potent and significantly less toxic than existing drugs, and is poised to enter global Phase 3 trials in 2022. Another compound, ABP-6016, has demonstrated safety and efficacy in preclinical trials for NASH, which is projected to become the most common cause of liver disease. To learn more about Atom Therapeutics visit our website.
7-day free trial · no credit card
Verified contacts
1
available on Kipplo
LinkedIn employees
4
11 to 50 range
Open roles
—
no listings
Distinct roles
0
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 1 verified contacts at Atom Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
1 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Sign up to unlock all 1 contacts at Atom Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 1 verified contacts at Atom Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.